Yehualashet Awgichew Shewasinad
Pharmacology and Toxicology Unit, Department of Pharmacy, College of Health Sciences, Debre Berhan University, Debre Berhan, Ethiopia.
Diabetes Metab Syndr Obes. 2020 Dec 4;13:4763-4777. doi: 10.2147/DMSO.S274844. eCollection 2020.
Diabetes mellitus (DM) is a chronic endocrine disease distinguished by hyperglycemia due to disturbance in carbohydrate or lipid metabolism or insulin function. To date, diabetes, and its complications, is established as a global cause of morbidity and mortality. The intended aim during the management of diabetes is to maintain blood glucose close to normal because the majority of patients have poor control of their elevated blood glucose and are highly prone to severe macrovascular and microvascular complications. To decrease the burden of the disease and its complications, scientists from various disciplines are working intensively to identify novel and promising drug targets for diabetes and its complications. Increased and ongoing investigations on mechanisms relating to diabetes and associated complications could potentially consider inflammatory cascades as a promising component of the strategy in the prevention and control of diabetes and its complications. The potential of targeting mediators of inflammation like toll-like receptors (TLRs) are part of current investigation by the scientific community. Hence, the aim of the present review is to discuss the role of TLRs as a potential drug target for diabetes and diabetes associated complications.
糖尿病(DM)是一种慢性内分泌疾病,其特征是由于碳水化合物、脂质代谢或胰岛素功能紊乱导致血糖升高。迄今为止,糖尿病及其并发症已成为全球发病和死亡的原因。糖尿病管理的目标是将血糖维持在接近正常水平,因为大多数患者对升高的血糖控制不佳,极易发生严重的大血管和微血管并发症。为了减轻该疾病及其并发症的负担,来自各个学科的科学家们正在深入研究,以确定针对糖尿病及其并发症的新的、有前景的药物靶点。对糖尿病及其相关并发症机制的不断深入研究可能会将炎症级联反应视为预防和控制糖尿病及其并发症策略中的一个有前景的组成部分。靶向炎症介质如Toll样受体(TLRs)的潜力是科学界当前研究的一部分。因此,本综述的目的是讨论TLRs作为糖尿病及糖尿病相关并发症潜在药物靶点的作用。